Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · January 02, 2023

Ingenol Mebutate Is Associated With Increased Reporting Odds for SCC in Patients With Actinic Keratosis

Journal of Cutaneous Medicine and Surgery

 

Additional Info

Journal of Cutaneous Medicine and Surgery
Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
J Cutan Med Surg 2022 Dec 10;[EPub Ahead of Print], PM Jedlowski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading